Search

• 

  GSK announces US regulatory submission seeking expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 mos+

  Media

  This vaccine is currently approved for active immunisation against influenza A subtype viruses and type B viruses

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-seeking-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-mosplus/

  First published: 02 February 2016

• GSK’s global HIV business ViiV Healthcare completes transactions to acquire Bristol-Myers Squibb’s R&D HIV assets

  Media

  ViiV Healthcare has completed two previously announced transactions with Bristol-Myers Squibb

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-global-hiv-business-viiv-healthcare-completes-transactions-to-acquire-bristol-myers-squibb-s-rd-hiv-assets/

  First published: 22 February 2016

• Results announcement for the first quarter 2015

  Media

  GSK reports Q1 sales of £5.6 billion; Core EPS of 17.3p (-16%) CER

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2015/

  First published: 06 May 2015

• GSK submits US regulatory filing of Arnuity Ellipta in children with asthma

  Media

  The sNDA is seeking approval for a dose of 50mcg once-daily, delivered using the Ellipta inhaler in this group of patients.

  https://www.gsk.com/en-gb/media/press-releases/gsk-submits-us-regulatory-filing-of-arnuity-ellipta-in-children-with-asthma/

  First published: 24 July 2017

• GSK’s Synflorix™ receives CHMP positive opinion for major label extension

  Media

  GSK announced that the CHMP of EMA has issued a positive opinion for the expansion of the SynflorixTM European label

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-synflorix-receives-chmp-positive-opinion-for-major-label-extension/

  First published: 27 July 2015

• GSK’s Nucala® (mepolizumab) receives approval from US FDA

  Media

  First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-nucala-mepolizumab-receives-approval-from-us-fda/

  First published: 04 November 2015

• GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD

  Media

  GSK and Theravance, Inc. today announced the start of a global phase III study, known as IMPACT.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-initiation-of-phase-iii-programme-with-fixed-dose-triple-combination-treatment-ffumecvi-in-patients-with-copd/

  First published: 16 July 2014

• GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma

  Media

  GSK updated results for Tafinlar® from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAFV600E metastatic melanoma.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-overall-survival-results-from-phase-iii-break-3-study-of-tafinlar-dabrafenib-in-patients-with-braf-v600e-mutant-metastatic-melanoma/

  First published: 29 September 2014

• New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age

  Media

  New data published in The Lancet from a Phase III clinical trial with Fluarix Tetra which prevented influenza in children 6 to 35 months

  https://www.gsk.com/en-gb/media/press-releases/new-clinical-data-demonstrate-high-vaccine-efficacy-of-fluarix-tetra-influenza-vaccine-in-children-6-35-months-of-age/

  First published: 06 March 2018

• Results announcement for the fourth quarter 2016

  Media

  View full Q4 2016 Results (PDF)

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2016/

  First published: 08 February 2017